...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: The slow bleed on low volume continues.....

All completed trials have dosed for six months or less. The ongoing BETONMACE will, at completion, dose patients for 12 to 24 months with an average 18 month dosing period, if the current trial design holds. BETonMACE dosing started November 2015, so we are 3 to 4 months in.

Share
New Message
Please login to post a reply